IS8047A - Kladríbínblöndur með bætta inngjöf um munn og gegnum slímhúð - Google Patents
Kladríbínblöndur með bætta inngjöf um munn og gegnum slímhúðInfo
- Publication number
- IS8047A IS8047A IS8047A IS8047A IS8047A IS 8047 A IS8047 A IS 8047A IS 8047 A IS8047 A IS 8047A IS 8047 A IS8047 A IS 8047A IS 8047 A IS8047 A IS 8047A
- Authority
- IS
- Iceland
- Prior art keywords
- mucosal administration
- improved oral
- cladribine formulations
- cladribine
- formulations
- Prior art date
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title 1
- 229960002436 cladribine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45892203P | 2003-03-28 | 2003-03-28 | |
| US48475603P | 2003-07-02 | 2003-07-02 | |
| US54124604P | 2004-02-04 | 2004-02-04 | |
| PCT/US2004/009384 WO2004087100A2 (en) | 2003-03-28 | 2004-03-26 | Cladribine formulations for improved oral and transmucosal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8047A true IS8047A (is) | 2005-09-26 |
Family
ID=33135981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8047A IS8047A (is) | 2003-03-28 | 2005-09-26 | Kladríbínblöndur með bætta inngjöf um munn og gegnum slímhúð |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20070065492A1 (https=) |
| EP (1) | EP1608343B1 (https=) |
| JP (1) | JP5412709B2 (https=) |
| KR (1) | KR20060011943A (https=) |
| CN (1) | CN101912615B (https=) |
| AU (2) | AU2004226435B2 (https=) |
| BR (1) | BRPI0408895A (https=) |
| CA (1) | CA2520522C (https=) |
| EA (1) | EA009714B1 (https=) |
| ES (1) | ES2584183T3 (https=) |
| HR (1) | HRP20050924A2 (https=) |
| IS (1) | IS8047A (https=) |
| ME (1) | MEP34508A (https=) |
| MX (1) | MXPA05010330A (https=) |
| NO (1) | NO20054944L (https=) |
| WO (1) | WO2004087100A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3332789B1 (en) | 2004-12-22 | 2022-04-06 | Merck Serono SA | Cladribine regimen for treating multiple sclerosis |
| JP2008524310A (ja) * | 2004-12-22 | 2008-07-10 | ラボラトワール セローノ ソシエテ アノニム | 多発性硬化症の組み合せ治療 |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| AU2007253254B2 (en) | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| CN100486645C (zh) * | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
| CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
| EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| WO2014075935A1 (de) | 2012-11-15 | 2014-05-22 | Sapiotec Gmbh | Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff |
| US9949947B2 (en) | 2012-12-11 | 2018-04-24 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| WO2015140790A1 (en) * | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| JP7138103B2 (ja) | 2016-11-29 | 2022-09-15 | オキュリス エスエー | 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造 |
| GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| EP3713582A1 (en) | 2017-11-24 | 2020-09-30 | Merck Patent GmbH | Cladribine regimen for use intreating progressive forms of multiple sclerosis |
| EP4670738A3 (en) | 2019-07-01 | 2026-03-04 | Oculis Operations Sàrl | Method for stabilizing the ph of an aqueous composition comprising a drug |
| CA3194812A1 (en) | 2020-09-10 | 2022-03-17 | Merck Patent Gmbh | Novel treatment regimen for the treatment of autoimmune disorders |
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
| US20240077481A1 (en) | 2021-03-03 | 2024-03-07 | Ares Trading S.A. | Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods |
| RU2758436C1 (ru) * | 2021-04-05 | 2021-10-28 | Общество с ограниченной ответственностью «ФармЭко» | Способ получения аморфных ко-эвапоратов кладрибина с циклодекстринами |
| US20260000606A1 (en) | 2022-06-15 | 2026-01-01 | Vektor Pharma Tf Gmbh | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases |
| TW202541818A (zh) | 2023-12-14 | 2025-11-01 | 瑞士商亞利斯貿易公司 | 用於治療重症肌無力之克拉屈濱(cladribine)療程 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
| HU181703B (en) | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
| JPS5838250A (ja) * | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | 複合体 |
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
| US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
| DE3317064A1 (de) | 1983-05-10 | 1984-11-15 | Consortium für elektrochemische Industrie GmbH, 8000 München | Verfahren zur herstellung von cyclooctaamylose |
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5106837A (en) * | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
| US4920214A (en) | 1986-04-16 | 1990-04-24 | American Maize-Products Company | Process for producing modified cyclodextrins |
| JPS62281855A (ja) * | 1986-05-29 | 1987-12-07 | Daikin Ind Ltd | ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物 |
| JP2575460B2 (ja) * | 1988-05-12 | 1997-01-22 | 東京田辺製薬株式会社 | ダナゾール−シクロデキストリン包接化合物 |
| HK1009335A1 (en) | 1989-04-03 | 1999-05-28 | Janssen Pharmaceutica N.V. | Regioselective substitutions in cyclodextrins |
| JPH035438A (ja) * | 1989-05-31 | 1991-01-11 | Kaken Pharmaceut Co Ltd | フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤 |
| EP0642347A4 (en) * | 1992-05-19 | 1997-06-18 | Scripps Research Inst | USE OF 2-HALO-ADENINE DERIVATIVES AS THERAPEUTIC ACTIVE AGENTS AGAINST CHRONIC-MYELOIC LEUKEMIA. |
| US5424296A (en) * | 1993-04-15 | 1995-06-13 | The Scripps Research Institute | 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma |
| US5510336A (en) * | 1994-09-06 | 1996-04-23 | Saven; Alan | 2-halo-2'-deoxyadenosine treatment for histiocytosis |
| CN1198655C (zh) * | 1995-11-23 | 2005-04-27 | 詹森药业有限公司 | 通过熔体挤出法制备的环糊精固体混合物 |
| JPH10265495A (ja) * | 1997-03-25 | 1998-10-06 | Meiji Milk Prod Co Ltd | フルオロプロゲステロン誘導体包接化合物 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP0940157A3 (de) | 1998-01-29 | 2000-06-14 | Hans Werner Prof. Lorenzen | Vorrichtung zur Stimulation von Körpergewebe |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| US6239118B1 (en) * | 1999-10-05 | 2001-05-29 | Richard A. Schatz | Method for preventing restenosis using a substituted adenine derivative |
| US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| ES2409884T3 (es) * | 2003-03-28 | 2013-06-28 | Ares Trading S.A. | Formulaciones orales de cladribina |
-
2004
- 2004-03-26 HR HR20050924A patent/HRP20050924A2/xx not_active Application Discontinuation
- 2004-03-26 JP JP2006509370A patent/JP5412709B2/ja not_active Expired - Lifetime
- 2004-03-26 AU AU2004226435A patent/AU2004226435B2/en not_active Expired
- 2004-03-26 CA CA2520522A patent/CA2520522C/en not_active Expired - Lifetime
- 2004-03-26 CN CN2010101265463A patent/CN101912615B/zh not_active Expired - Lifetime
- 2004-03-26 MX MXPA05010330A patent/MXPA05010330A/es active IP Right Grant
- 2004-03-26 ME MEP-345/08A patent/MEP34508A/xx unknown
- 2004-03-26 EP EP04758440.4A patent/EP1608343B1/en not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408895-6A patent/BRPI0408895A/pt not_active IP Right Cessation
- 2004-03-26 EA EA200600403A patent/EA009714B1/ru not_active IP Right Cessation
- 2004-03-26 WO PCT/US2004/009384 patent/WO2004087100A2/en not_active Ceased
- 2004-03-26 US US10/551,094 patent/US20070065492A1/en not_active Abandoned
- 2004-03-26 ES ES04758440.4T patent/ES2584183T3/es not_active Expired - Lifetime
- 2004-03-26 KR KR1020057018337A patent/KR20060011943A/ko not_active Ceased
-
2005
- 2005-09-26 IS IS8047A patent/IS8047A/is unknown
- 2005-10-25 NO NO20054944A patent/NO20054944L/no not_active Application Discontinuation
-
2009
- 2009-10-15 AU AU2009227811A patent/AU2009227811B2/en not_active Expired
-
2010
- 2010-09-27 US US12/891,492 patent/US8623408B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101912615A (zh) | 2010-12-15 |
| EP1608343A2 (en) | 2005-12-28 |
| JP2006526009A (ja) | 2006-11-16 |
| JP5412709B2 (ja) | 2014-02-12 |
| BRPI0408895A (pt) | 2006-04-11 |
| AU2009227811B2 (en) | 2012-02-02 |
| ES2584183T3 (es) | 2016-09-26 |
| KR20060011943A (ko) | 2006-02-06 |
| AU2009227811A1 (en) | 2009-11-05 |
| HRP20050924A2 (en) | 2006-08-31 |
| MEP34508A (en) | 2011-02-10 |
| WO2004087100A2 (en) | 2004-10-14 |
| AU2004226435B2 (en) | 2009-11-12 |
| NO20054944L (no) | 2005-11-24 |
| NO20054944D0 (no) | 2005-10-25 |
| US8623408B2 (en) | 2014-01-07 |
| EP1608343B1 (en) | 2016-04-27 |
| CA2520522A1 (en) | 2004-10-14 |
| WO2004087100A3 (en) | 2005-03-03 |
| AU2004226435A1 (en) | 2004-10-14 |
| CA2520522C (en) | 2012-05-29 |
| US20110015145A1 (en) | 2011-01-20 |
| CN101912615B (zh) | 2013-03-27 |
| US20070065492A1 (en) | 2007-03-22 |
| EA200600403A1 (ru) | 2006-08-25 |
| MXPA05010330A (es) | 2006-05-31 |
| EA009714B1 (ru) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8047A (is) | Kladríbínblöndur með bætta inngjöf um munn og gegnum slímhúð | |
| PT1501534E (pt) | Formulacoes farmaceuticas | |
| ATE336264T1 (de) | Dispergierbare pharmazeutische zusammensetzungen | |
| GB0210397D0 (en) | Pharmaceutical formulations | |
| TWI371252B (en) | Oral care implement | |
| NO20040125L (no) | Enterale formuleringer | |
| NO20050132D0 (no) | Vaksinesammensetning | |
| DK1827363T3 (da) | Antibakteriel og antiinflammatorisk oral plejesammensætning | |
| GB0302671D0 (en) | Pharmaceutical formulations | |
| ATE324882T1 (de) | In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit agomelatin | |
| GB2391809B (en) | Pharmaceutical composition comprising honey | |
| IL172824A0 (en) | Pharmaceutical formulations | |
| NO20041383L (no) | Flashsmelte oral doseringsformulering | |
| GB2392093B (en) | Pharmaceutical formulations | |
| DK1589938T3 (da) | Mundplejesammensætninger og fremgangsmåder hertil | |
| DE60326998D1 (de) | Orale zubereitung | |
| GB0302672D0 (en) | Pharmaceutical formulations | |
| IL166337A0 (en) | Oral administration of calctionin | |
| GB0325383D0 (en) | Oral formulations | |
| GB0316341D0 (en) | Pharmaceutical formulations | |
| UA8116S (uk) | Камера терапевтична індивідуальна | |
| GB2403407B (en) | Palatable oral anthelmintic composition | |
| PL377147A1 (pl) | Doustna kompozycja | |
| IL174308A0 (en) | Therapeutic formulations | |
| GB0225926D0 (en) | Pharmaceutical paste formulations |